Brief: AB Science: Phase 2B/3 Masitinib Study In Alzheimer's Disease Meets Primary Endpoint

AB Science SA

16/12/2020 06:56

Dec 16 (Reuters) - AB Science SA  ABS.PA :
    * REG-AB SCIENCE ANNOUNCES THAT PHASE 2B/3 STUDY EVALUATING
ORAL
IN ALZHEIMER’S DISEASE MET ITS PRIMARY ENDPOINT
    * THERE WERE SIGNIFICANTLY FEWER PATIENTS REACHING SEVERE
DEMENTIA
STAGE (MMSE<10) WITH MASITINIB 4.5 MG/KG/DAY
    * SAFETY OF MASITINIB 4.5 MG/KG/DAY WAS ACCEPTABLE AND
CONSISTENT
WITH KNOWN TOLERABILITY PROFILE FOR MASITINIB
    * A NEW PATENT WAS FILED BASED ON RESULTS FROM STUDY AB09004
    * PATENT WOULD PERMIT AB SCIENCE TO RETAIN EXCLUSIVE RIGHTS
ON USE
OF MASITINIB IN ALZHEIMER'S DISEASE UNTIL 2041

Source text for Eikon:  ID:nGNE9TCKYJ 
Further company coverage:  ABS.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))